• 한국임상수의학회지
• /
• 제30권4호
• /
• pp.315-319
• /
• 2013

5년령의 중성화된 암컷 말티즈가 1개월 동안 지속된 전신적 발적, 탈모 및 소양감으로 내원하였다. 피부조직구증으로 진단되어 면역억제치료를 1개월 간 지속하였지만 다발성의 발적된 반 및 판 병변들이 새롭게 발생하였다. 피부병변에 대한 압박도말검사에서 림프종을 지시하는 원형세포들이 관찰되었다. 조직학적 검사에서는 종양세포들의 외피 및 부속구조물에 대한 친화성이 나타났다. 면역염색결과 종양세포들은 CD3에 대하여 양성, CD79a에 대해서는 음성반응을 나타내어 피부 상피친화성 T-세포 림프종으로 확진하였다. $70mg/m^2$의 lomustine을 2-3주 간격으로 총 2회 투여하였으며 부분적인 치료반응이 관찰되었다. 피부병변의 악화와 lomustine의 이용제한으로 gemcitabine ($500mg/m^2$, 1주일당 1회 30분간 혈관주입)을 이용한 화학치료를 시작하였다. 총 3회 치료가 실시되었으나 질병의 진행을 억제하지 못하였으며, 최초 lomustine 치료 69일 후 안락사 되었다.

• 한국임상수의학회지
• /
• 제29권4호
• /
• pp.328-330
• /
• 2012

본 환축은 안구진탕, 좌측 편측보행을 주증으로 내원하여 MRI 검사 및 조직병리학적 검사로 수막종으로 진단 하였다. 초기에 prednisolone과 hydroxyyrea를 투약하였으나 증상의 악화로 중단하였으며, 이후 lomustine 화학요법을 실시하여 임상 증상이 개선되어 유지해오다가 증상이 발현 된지 18개월째에 자연사한 증례이다.

• 한국임상수의학회:학술대회논문집
• /
• 한국임상수의학회 2008년도 추계학술대회
• /
• pp.143-143
• /
• 2008

• 한국임상수의학회지
• /
• 제26권3호
• /
• pp.263-267
• /
• 2009

A 9-year-old, female, Maltese Dog(2.15 kg of body weight) was referred to the Veterinary Medical Teaching Hospital, Chungnam National University with cervical masses, abdominal masses and petechia. Physical examination showed masses in mandibular, prescapular, inguinal, popliteal lymph node and abdominal subcutaneous hemorrhage. This case was diagnosed as the multicentric lymphoma by physical examination, laboratory examination, radiography, ultrasonography, CT, fine needle aspiration and histopathologic examination. This dog was treated by low-budget protocol with lomustine and prednisolone. The dog show that response duration and survival time is 143days and 263 days, respectively.

• 한국임상수의학회지
• /
• 제34권2호
• /
• pp.94-97
• /
• 2017

A 10-year-old male Schnauzer dog presented with a 1-week history of ataxia, right-sided hemiparesis, and right-sided head tilt. On the basis of magnetic resonance imaging (MRI) with neurological examination and cerebrospinal fluid analysis results, a primary brain tumor was suspected. Therapy with imatinib mesylate plus hydroxyurea for 7 weeks was not effective and clinical signs worsened. Chemotherapy was then changed to lomustine plus hydroxyurea. Although the existing clinical signs continued, they did not deteriorate. No change in mass size was observed in subsequent MRI. The subject suddenly died from dyspnea 388 days after initial presentation. In this case, choroid plexus papilloma was definitively diagnosed based on histopathological findings.

• 한국임상수의학회지
• /
• 제36권3호
• /
• pp.180-183
• /
• 2019

A 7-year-old, male Maltese dog with a body weight of 2.8 kg was presented with a history of hind limbs ataxia that progressed to tetraparesis over a one-month period. Based on physical and neurological examinations, tetraparesis with concomitant UMN signs, kyphosis and severe neck pain were identified. On MRI scan, we tentatively diagnosed this patient as a primary intramedullary spinal cord tumor. Therapy with lomustine plus hydroxyurea and prednisolone was initiated and the clinical signs rapidly improved. The patient was regularly checked by MRI scan and the range of the mass was gradually reduced to complete remission for 11 months. About 19 months after treatment, the patient showed anemia and hematochezia which suspected as adverse effects of chemotherapy. The condition was getting worse over 2 months and the patient suddenly expired 657 days after initial presentation. On histopathological examination, the spinal cord sample was identified as a neuronal atrophy without evidence of tumor cell.

• 한국임상수의학회지
• /
• 제35권4호
• /
• pp.150-154
• /
• 2018

A 9-month-old, castrated, male Labrador Retriever was referred for generalized progressing cutaneous reddish mass lesions with bleeding, scale, crust, and pruritus. On the basis of histopathological findings and the results of immunochemical staining, cutaneous nonepitheliotropic B-cell lymphoma was identified. A cyclophosphamide-doxorubicin-vincristine-prednisolone (CHOP)-based chemotherapy regimen was initiated, and the patient initially showed partial response to vincristine and $\text\tiny{L}$-asparaginase, but the cutaneous lesions progressed gradually. After the first cycle of the CHOP-based protocol, lomustine was administered instead. The cutaneous lesions showed partial response to lomustine, but the treatment did not stop the progression of cutaneous lymphoma. The patient was euthanized due to neurologic signs, including reduced consciousness and seizures, 53 days after initial presentation. The postmortem histopathological examination showed systemic metastasis involving the lymph nodes, skin, kidney, ureter, liver, brain, temporal muscle, diaphragmatic muscle, conjunctiva, and oral cavity.

• 한국임상수의학회지
• /
• 제36권1호
• /
• pp.30-37
• /
• 2019

The purpose of this present study was to objectively evaluate gastrointestinal and bone marrow AEs after administration of various chemotherapeutic agents in canines with malignant tumors, using the Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE), which includes descriptive terminology used for adverse events (AEs) reported in dogs and cats. The medical records of 42 dogs with malignant tumor that underwent chemotherapy were reviewed retrospectively. There were no significant differences in the prevalence of gastrointestinal AEs among the 5 chemotherapeutic agents (vincristine, cyclophosphamide, doxorubicin, lomistine, and carboplatin). The prevalence of bone marrow AEs was significantly higher after administration of lomustine than after administration of vincristine or doxorubicin. Grade 1 AEs of the gastrointestinal tract and bone marrow were most often observed after administration of various chemotherapeutic agents. Delayed and cumulative myelosuppression of lomustine in some dogs receiving regular blood examination were identified. The findings of this study will help predict possible gastrointestinal and bone marrow AEs due to the use of chemotherapeutic agents to treat canines with malignant tumors.

• 한국임상수의학회지
• /
• 제40권6호
• /
• pp.445-451
• /
• 2023

An 8-year-old female pet rabbit presented at the veterinary clinic for mammary gland palpation due to the presence of a mass. Upon physical examination, a mass was identified in the left fourth mammary gland. Abdominal ultrasonography revealed a 3 × 2 cm mass in the right uterus and general thickening of the endometrium, suggesting uterine sinusitis. Multiple pulmonary nodules suspected to be metastatic lesions were identified on chest radiography. Surgery was performed to mastectomy and ovariohysterectomy (OHE). The histopathological examination of the tumor revealed mammary gland adenocarcinoma (simple-type) with multiple nodules consisting of the proliferation of tumor cells forming tubules containing secretory materials, cellular debris, and solid nests with a central area of necrosis. Metronomic chemotherapy was performed with cyclophosphamide and lomustine (CCNU) based on the histopathological findings. The quality of life has been well maintained, with no specific clinical symptoms observed for 8 months after metronomic chemotherapy. To the best of authors' knowledge, this study is the first to examine the effects of metronomic chemotherapy with cyclophosphamide and lomustine in a pet rabbit.

• Journal of Korean Neurosurgical Society
• /
• 제51권4호
• /
• pp.199-202
• /
• 2012

Objective: This retrospective study was performed to evaluate the role of chemotherapy in the management of patients with anaplastic astrocytoma (AA). Methods: We compared the survival outcome among the 3 different treatment protocol groups in a single institution. A total of 86 patients (39 men and 47 women) with newly diagnosed AA after surgery were analyzed. Among them, 31 patients (36.0%) were treated with radiotherapy only (RT Group), 30 patients (34.9%) were treated with nimustine-cisplatin chemotherapy before RT (ACNU-COOP group), and 25 patients (29.1 %) were treated with procarbazine, lomustine and vincristine (PCV) chemotherapy after radiotherapy (PCV group). Results: The median survival was 14.0, 30.0 and 72.0 months in RT, ACNU-COOP, and PCV group, respectively and showed significant differences (RT vs. ACNU-COOP; p=0.039, RT vs. PCV; 0.002, ACNU-COOP vs. PCV; 0.045). PCV group showed less toxicity rate (5 patients; 20%) than ACNU-COOP group (12 patients; 40%), while only 3 patients (9.6%) in RT group experienced grade 3 or 4 toxicities. Conclusion: An application of chemotherapy before or after radiotherapy is beneficial in prolonging the survival of patients with AA. Adjuvant PCV chemotherapy after radiotherapy is recommendable.